Newer generation epilepsy drugs continue to take market share
Older epilepsy drugs continue to be used by many patients in the UK, but newer generation therapies will increasingly be adopted over the next ten years, a report has claimed.
The latest country report from GlobalData, entitled ‘PharmaPoint: Epilepsy UK Drug Forecast and Market Analysis to 2022′, provides an overview of the market for antiepileptic drugs (AEDs).
It observes that the market is driven by therapies aimed at reducing the frequency of seizures, with UCB’s Keppra (levetiracetam) and GlaxoSmithKline’s Lamictal (lamotrigine) being the most dominant treatments.
According to GlobalData, these two drugs “form the mainstay of epilepsy treatment … and will continue to have significant market share during the forecast period”.
Other older generation drugs that currently play a key role in epilepsy treatment include Pfizer’s Dilantin (phenytoin), Abbott’s Depakote (divalproex sodium) and Novartis’ Tegretol (carbamazepine) and Trileptal (oxcarbazepine).
However, the report predicts a continued shift towards newer first-in-class drugs, such as GlaxoSmithKline’s Trobalt/Potiga (retigabine/ezogabine) and Eisai’s Fycompa (perampanel) over the coming years.
Posted by Steve Long